Mechanism, evidence, and regulatory status for 52 of the most-discussed compounds in circulation — including nine that are sold as peptides but are not peptides at all. We publish what the research actually shows, including, often, that it shows very little.
Most peptide information online flattens everything into one confident voice — an FDA-approved drug with 20,000 trial participants reads the same as a tetrapeptide with no receptor and no replication. We grade each entry so the distinction is visible before you read a word of the biology.
NAD+ is a dinucleotide coenzyme. MK-677 is a spiropiperidine. 5-Amino-1MQ is a quinolinium small molecule. HCG is a glycoprotein hormone. They are sold by peptide vendors, filed under peptides, and discussed as peptides — and not one of them is an amino acid chain. We include them, because pretending they are not part of this world helps nobody, and we label them. Every profile that is not a peptide says so at the top.
Organised by what these molecules actually do at the receptor, not by the outcome someone hopes to sell.
Incretin and amylin pathways — the most clinically validated class here.
11 ENTRIESGHRH analogs and ghrelin-receptor secretagogues acting on pituitary GH release.
7 ENTRIESCytoprotection and tissue healing. Heavy preclinical literature, thin human evidence.
2 ENTRIESThymic peptides modulating T-cell maturation and innate signalling.
7 ENTRIESMitochondrial-derived peptides and membrane-targeting agents.
5 ENTRIESPeptides acting on CNS signalling, cognition, and anxiety.
4 ENTRIESMelanocortin receptor agonists — the widest safety spread in the library.
4 ENTRIESUpstream regulators of the hypothalamic-pituitary-gonadal axis.
2 ENTRIESTopical peptides — the one group where delivery, not mechanism, is the hard part.
Regulatory status moved twice in three years and is before an FDA advisory committee now.
Tier 3 · Limited Human DataOne of the few peptides here with a definitive human answer — it failed Phase 2b.
Tier 3 · Limited Human DataNot a peptideNot a peptide, barely crosses membranes, and sold by the IV bag anyway.
Tier 1 · FDA ApprovedApproved, and its unapproved sibling Melanotan II is the whole lesson.
We do not publish dosing, reconstitution, administration, or cycling protocols. Not for any peptide on this site, including the FDA-approved ones. This is a deliberate editorial line, and it is worth explaining plainly rather than burying in a disclaimer.
For unapproved substances, no honest dosing guidance exists to give. A protocol implies a known therapeutic window — a dose demonstrated to produce a benefit at an acceptable risk in humans. For most peptides in this library, that work has never been done. Publishing numbers anyway would manufacture a false impression of established practice out of forum consensus and vendor copy.
For the approved ones, dosing is a physician's job, individualised to a patient, with monitoring. A web page is not a substitute for that, and pretending otherwise helps nobody.
Receptor-level mechanism, an honest account of what has and has not been demonstrated in humans, current regulatory status including where it is actively changing, and the documented safety signals — cited, and graded.